News
-
Sep. 30, 2022EnPlusOne Biosciences Launches Enzymatic RNA Synthesis Platform with $12 Million in Seed Financing
EnPlusOne Biosciences, Inc., a biotechnology company harnessing the power of enzymes to synthesize RNA oligonucleotides, today formally launched with $12 million in seed financing. The round was led by Northpond Ventures with participation from Breakout Ventures, Coatue, and angel investors. The financing will support continued development and scaling of the company’s proprietary ezRNA™ synthesis platform in line with the company’s mission to enable next-generation solutions for emerging RNA therapeutics.
-
Sep. 01, 2022Daniel Wiegand on the RNA Revolution
We’re in the midst of an RNA revolution, and Daniel Wiegand and his team are prepared to deliver RNA to the world by making high-quality RNA oligonucleotides cheaper and more easily accessible. After an impactful co-op experience at a pharmaceutical company during his undergraduate years, Daniel understood what it truly meant to be a scientist, and he was hooked. His passion for cutting-edge, impactful science brought him to the Wyss, where he is leading the development of a manufacturing platform for the enzymatic synthesis of RNA oligonucleotides for use in therapeutics. Learn more about Daniel and his work in this month’s Humans of the Wyss.